2014
Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities
Heimer R, Eritsyan K, Barbour R, Levina OS. Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. BMC Infectious Diseases 2014, 14: s12. PMID: 25253447, PMCID: PMC4178532, DOI: 10.1186/1471-2334-14-s6-s12.Peer-Reviewed Original ResearchMeSH KeywordsAdultCitiesFemaleHepatitis CHumansMalePrevalenceRussiaSeroepidemiologic StudiesSubstance Abuse, IntravenousYoung AdultConceptsHepatitis C virusRespondent-driven samplingHIV-1Hepatitis C virus (HCV) seroprevalencePositive HCV serostatusInjection drug useLarger social network sizeHarm reduction programsHCV-positive serostatusBetter prevention programsHCV prevalenceHCV serostatusHCV epidemicMean ageC virusInjection paraphernaliaVirus seroprevalenceSerological testingRisk populationsBlood specimensCity-level factorsPWIDDrug usePrevention programsLonger duration
2013
Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population.
Akselrod H, Grau LE, Barbour R, Heimer R. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. American Journal Of Public Health 2013, 104: 1713-21. PMID: 24134382, PMCID: PMC3990658, DOI: 10.2105/ajph.2013.301357.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis B virusDrug use durationSubstance abuse treatmentB virusRisk factorsCriminal justice involvementDrug usersAbuse treatmentAdult injection drug usersSeroprevalence of HIVInjection drug usePotential risk factorsSignificant predictorsUse durationMultiple viral infectionsEffective harm reduction strategiesHarm reduction strategiesJustice involvementHCV seroprevalenceInjection useInterim analysisViral infectionDrug useSerological tests